Providing Independent Validation for a HealthTech Investment DecisionNBFC
The VC’s internal team had conducted initial diligence and was optimistic about the opportunity. However, given the clinical and regulatory complexities, they wanted an independent, third-party assessment to validate their views and highlight any blind spots before proceeding to term sheet.
Service Focus: Investor Advisory – Align
Industry: HealthTech – Remote Diagnostics & AI-based Screening
challenge
- Startup lacked documented clinical validation or third-party trials
- Unclear classification of their product under medical device or telehealth regulations
- GTM plan mixed B2B (hospitals) and B2C (app) models without prioritization
- Financial model included assumptions inconsistent with industry benchmarks
- Founders had limited experience in navigating regulatory and hospital procurement frameworks
our approach
-
Capital Crest Consulting was engaged to conduct a structured and independent assessment of the startup’s business model, GTM, regulatory risk, and founder readiness. Our evaluation covered:
1. Business Model & Revenue Logic Review
2. GTM Viability & Channel Scalability
3. Compliance & Risk Landscape
4. Founding Team Evaluation (Strategic Readiness & Governance Maturity)We also held structured interviews with the founding team and reviewed their onboarding process with hospital partners.
key intervention
- Delivered a red-flag matrix categorizing business, compliance, and execution risks
- Evaluated monetization logic across 3 models: hospital-driven, diagnostics-led, and B2C
- Mapped unit economics and operational assumptions to real-world industry scenarios
- Assessed founder responses to investor-facing objections and board-level readiness
- Offered governance recommendations for post-investment oversight
the solution
- The VC received a structured report outlining risk categories and decision triggers
- Our findings supported several internal views, while also highlighting key compliance gaps
- Recommendations were made for risk mitigants, including formalizing a clinical advisory board
- VC chose to continue discussions with a revised deal structure and milestone-based funding
- The startup appreciated the feedback loop and aligned internal strategy to reflect key takeaways
strategic insight
For VCs, an external view isn’t about replacing internal evaluation—it’s about enhancing conviction. In regulated sectors like HealthTech, structured advisory can turn risk into informed opportunity.